Skip to content

May 7, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
M&A / Deals
Halozyme and Oruka sign agreement for Hypercon technology

M&A / Deals

Halozyme and Oruka sign agreement for Hypercon technology

Pharmaceutical Technology

Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics to develop ORKA-001 using Hypercon Technology.

Read full story

pharminent May 7, 2026 (Last updated: May 7, 2026)

Pharmaceutical Technology

Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics to develop ORKA-001 using Hypercon Technology.

Read full story

Post navigation

Previous: Novo Nordisk Raises Guidance on Strong Wegovy Pill Launch

Next: Daiichi Sankyo and Waiv partner for ADC biomarkers

Related Stories

M&A / Deals

Angelini inks $4.1B Catalyst buy to enter US rare disease market

pharminent May 7, 2026

M&A / Deals

Roche buys AI-powered diagnostics player PathAI

pharminent May 7, 2026

M&A / Deals

Daiichi Sankyo and Waiv partner for ADC biomarkers

pharminent May 7, 2026

You May Have Missed

Regulatory

FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit

pharminent May 7, 2026

M&A / Deals

Angelini inks $4.1B Catalyst buy to enter US rare disease market

pharminent May 7, 2026

Regulatory

Bayer plans filings for cardiac amyloidosis imaging agent

pharminent May 7, 2026

M&A / Deals

Roche buys AI-powered diagnostics player PathAI

pharminent May 7, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.